Trius Therapeutics, Inc. (TSRX)

[TRUISM]

Will payment be made under the Trius Contingent Value Rights?

In January 2015, Merck & Co., Inc. (“Merck”) acquired Cubist Pharmaceuticals, Inc. (“Cubist”) which, in 2013, had acquired Trius Therapeutics (“Trius”). The contingent value rights (“CVRs”) received by Trius shareholders as part of the 2013 Trius/Cubist transaction remained an obligation of Cubist, now a wholly- owned Merck subsidiary.

Payments were to be made under those CVRs only if SIVEXTRO (tedizolid phosphate) achieved $125 million in net sales in 2016 in specified territories. Net sales for SIVEXTRO in 2016 were $14 million; therefore payment will not be made under the Trius CVRs.

I didn't opt for the CVR's due to the feeling tedizolid wouldn't be pushed aggressively enough, as to meet the milestone....



Blessings to All

TRUTH